Renal Stones (Urolithiasis)

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Urolithiasis (kidney stone disease) is one of the most common urological conditions worldwide, with a lifetime prevalence of 10-15% in industrialized countries. [1,2] The condition is characterized by the formation of crystalline deposits within the urinary tract, most commonly in the renal pelvis and calyces. Clinical manifestations occur when stones migrate into the ureter, causing obstruction, proximal dilation (hydronephrosis), and severe colicky pain from capsular distension and ureteric spasm. [3]

The disease burden is substantial: urolithiasis accounts for over 1 million emergency department visits annually in the United States alone, with direct healthcare costs exceeding $10 billion. [4] Recurrence rates are high, with approximately 50% of patients experiencing a second stone episode within 5-10 years without preventive measures. [5]

Key Clinical Emergency: The combination of obstruction plus infection (obstructed infected kidney or pyonephrosis) constitutes a true urological emergency. This "pus under pressure" scenario can rapidly progress to urosepsis and requires urgent decompression—antibiotics alone cannot penetrate the obstructed system. [6] Failure to recognize and treat this emergency within 24 hours significantly increases morbidity and mortality.

---

2. Epidemiology

Urolithiasis demonstrates significant geographic, demographic, and temporal variations that reflect both genetic predisposition and environmental influences.

Demographic Risk Factors

Male Predominance: The 2-3:1 male-to-female ratio is attributed to protective effects of estrogen (which increases urinary citrate excretion, a stone inhibitor) and testosterone's influence on oxalate metabolism. [9] This gap has narrowed in recent decades, possibly due to changing dietary patterns and obesity rates in women. [13]

Age Distribution: While peak incidence occurs between 30-50 years, first-time stone formers are increasingly seen in younger populations (including children), correlating with rising obesity and metabolic syndrome rates. [14]

Ethnicity: Caucasians and Asians have higher stone prevalence than African-Americans and Hispanic populations in the United States, though socioeconomic factors and dietary habits confound these observations. [15]

Temporal Trends

The prevalence of kidney stones has increased by approximately 70% over the past 30 years in developed countries. [16] This dramatic rise is attributed to:

• Increasing obesity and metabolic syndrome
• Western dietary patterns (high animal protein, sodium, refined sugars)
• Climate change and global warming (increased dehydration)
• Sedentary lifestyle
• Greater diagnostic sensitivity with widespread CT imaging

Seasonal Variation

Stone presentations peak 2-3 months after periods of high ambient temperature, reflecting dehydration-induced urinary concentration. [17] This "stone season" effect is most pronounced in hot climates and during summer months.

---

3. Stone Composition and Classification

Understanding stone composition is critical for metabolic evaluation, prevention strategies, and predicting response to treatment.

Stone Types: Composition and Characteristics

Calcium Stones (80-85% combined)

Calcium Oxalate: The most common stone type worldwide. [18] Forms when urinary calcium or oxalate concentration exceeds saturation threshold. Crystallizes in two forms:

• Calcium oxalate monohydrate (COM): Hard, smooth, dark brown ("jackstone" appearance)
• Calcium oxalate dihydrate (COD): Softer, more irregular

Risk Factors:

• Hypercalciuria (> 250 mg/24h in women, > 300 mg/24h in men): Most common metabolic abnormality (40-60% of calcium stone formers) [19]
  • Absorptive hypercalciuria (increased intestinal calcium absorption)
  • Resorptive hypercalciuria (hyperparathyroidism)
  • Renal leak hypercalciuria (impaired renal calcium reabsorption)
• Hyperoxaluria: Dietary excess (spinach, rhubarb, nuts, chocolate) or enteric (inflammatory bowel disease, chronic diarrhea, bariatric surgery) [20]
• Hypocitraturia: Citrate is a key stone inhibitor; low levels in chronic diarrhea, distal RTA, thiazide use
• Low urine volume: Dehydration (urine output less than 1.5 L/day significantly increases risk) [21]

Calcium Phosphate: Often coexists with calcium oxalate. Strongly associated with:

• Renal tubular acidosis (type 1 distal RTA): Alkaline urine promotes phosphate crystallization
• Hyperparathyroidism: Hypercalcemia and hypercalciuria

Uric Acid Stones (5-10%)

Critical Feature: Radiolucent (invisible on plain radiography). Must be diagnosed with CT or ultrasound. [22]

Pathogenesis: Three factors must align:

1. Low urine pH (less than 5.5) - most important factor [23]
2. Hyperuricosuria (> 800 mg/24h in men, > 750 mg/24h in women)
3. Low urine volume

Risk Factors:

• Gout and hyperuricemia
• High purine diet: Red meat, seafood, alcohol (especially beer)
• Metabolic syndrome: Insulin resistance causes impaired renal ammonia production → acidic urine [24]
• Chronic diarrhea: Bicarbonate loss → metabolic acidosis → acidic urine
• Myeloproliferative disorders: Increased cell turnover → uric acid production

Clinical Pearl: Uric acid stones are unique in being chemically dissolvable through urinary alkalinization (target pH 6.5-7.0) using potassium citrate or sodium bicarbonate. [25]

Struvite Stones (5-10%)

Also called "infection stones" or "triple phosphate" (magnesium ammonium phosphate). [26]

Pathogenesis: Requires chronic infection with urease-producing bacteria:

• Proteus mirabilis (most common)
• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Staphylococcus saprophyticus

Urease enzyme splits urea → ammonia + CO₂ → alkaline urine (pH > 7.2) → struvite and carbonate apatite precipitation.

Clinical Features:

• Staghorn calculi: Large branching stones that fill the renal pelvis and calyces (named for resemblance to deer antlers)
• Rapid growth (can form within weeks)
• Recurrent UTIs
• More common in women (due to higher UTI rates)
• Associated with neurogenic bladder, urinary stasis, indwelling catheters

Management Challenge: Stones harbor bacteria within crystalline matrix, making eradication with antibiotics alone impossible. Requires complete surgical removal + prolonged antibiotics. [27]

Cystine Stones (1-2%)

Genetic Disease: Autosomal recessive defect in cystine transporter (SLC3A1 or SLC7A9 genes) → impaired renal tubular reabsorption of cystine, ornithine, lysine, arginine (COLA). [28]

Clinical Features:

• Present in childhood/young adults (usually before age 30)
• Bilateral recurrent stones
• Faint radiopacity (semi-opaque) on X-ray
• Pathognomonic hexagonal crystals on urine microscopy
• Yellow-brown color on gross inspection

Diagnosis: 24-hour urine cystine excretion > 250 mg/day (normal less than 30 mg/day)

Management:

• High fluid intake (> 3 L/day)
• Urinary alkalinization (target pH > 7.0)
• Cystine-binding thiol drugs: D-penicillamine, tiopronin (chelate cystine into soluble complex)

---

4. Pathophysiology

Stone Formation: A Multi-Step Process

Stone development requires a sequence of physicochemical events occurring in urine: [29]

1. Supersaturation

Urine becomes supersaturated when solute concentration exceeds its solubility threshold at a given pH and temperature. This creates a thermodynamically unstable solution where crystal precipitation becomes energetically favorable.

Key Factors Increasing Supersaturation:

• Low urine volume: Most important modifiable risk factor [21]
• High dietary solute load (calcium, oxalate, uric acid, sodium)
• Urinary pH extremes (acidic for uric acid; alkaline for calcium phosphate/struvite)

2. Nucleation

Initial crystal formation from supersaturated urine. Two types:

• Homogeneous nucleation: Spontaneous crystal formation in pure solution (requires extreme supersaturation)
• Heterogeneous nucleation: Crystal formation on existing surfaces (epithelial cells, other crystals, debris) - clinically more common

3. Crystal Growth and Aggregation

Microscopic crystals grow by incorporating additional ions from supersaturated urine. Individual crystals aggregate into larger particles. Randall's plaques (subepithelial calcium phosphate deposits in renal papillae) serve as nidus for calcium oxalate stone formation. [30]

4. Crystal Retention

For clinically significant stones to form, crystals must be retained in the urinary tract long enough to grow to obstructive size (typically > 2-3 mm). Normally, crystals are flushed out by urine flow before growing large. Retention occurs when:

• Anatomical abnormalities create stasis (PUJ obstruction, calyceal diverticulum, horseshoe kidney)
• Attachment to tubular epithelium or Randall's plaques
• Crystal aggregation overwhelms urine flow

Stone Inhibitors: Natural Defense Mechanisms

Normal urine contains multiple substances that inhibit crystallization: [31]

Clinical Implication: Citrate supplementation (potassium citrate 30-60 mEq/day) reduces stone recurrence by 80-90% in patients with hypocitraturia. [32]

Anatomical Sites of Ureteric Impaction

Stones typically lodge at three natural ureteric narrowings: [3]

1. Pelvi-Ureteric Junction (PUJ): Transition from renal pelvis to ureter (narrowest point of upper tract)
2. Pelvic Brim: Where ureter crosses iliac vessels
3. Vesico-Ureteric Junction (VUJ): Most common site of impaction; narrowest part of entire ureter (2-3 mm diameter)

Size Prediction for Spontaneous Passage:

• less than 5 mm: 80-90% pass spontaneously
• 5-7 mm: 50-60% pass spontaneously

• 7 mm: less than 20% pass spontaneously [33]

Hydronephrosis and Capsular Stretch

When a stone obstructs the ureter:

1. Continued urine production by glomeruli increases proximal pressure
2. Pelvicalyceal system distends (hydronephrosis)
3. Renal capsule stretches → severe visceral pain
4. Ureteric peristalsis attempting to propel stone → colicky nature of pain
5. Prolonged obstruction → decreased GFR → eventual renal damage

Timeline of Renal Damage: Irreversible renal injury occurs after:

• Partial obstruction: 6-12 weeks
• Complete obstruction: 4-6 weeks [34]

---

5. Clinical Presentation

Classic Renal Colic

Pain Characteristics: [3]

• Location: Flank/loin pain radiating to ipsilateral groin, testis/labium
• Quality: Excruciating, described as "worst pain ever" (10/10 severity)
• Pattern: Colicky (waves of intense pain with partial relief between spasms)
• Onset: Sudden, often waking patient from sleep
• Duration: Typically 20-60 minutes per episode, but can persist for hours
• Movement: Patient cannot find comfortable position, constantly moving (pathognomonic feature distinguishing from peritonitis)

Radiation Pattern (reflects stone location):

• Upper/mid ureter: Flank pain alone
• Lower ureter: Pain radiates to groin, ipsilateral testicle/labium majus
• Intramural ureter/VUJ: Lower abdominal pain, urinary frequency, urgency, dysuria

Associated Symptoms

Red Flag Presentations: Urological Emergencies

Exam Detail: #### 1. Obstructed Infected Kidney (Pyonephrosis)

Definition: Infected hydronephrosis - "pus under pressure" [6]

Clinical Features:

• Renal colic PLUS fever > 38°C
• Systemic sepsis signs: tachycardia, hypotension, rigors
• May lack typical sepsis localizing symptoms if obstruction is complete

Pathophysiology: Obstruction prevents drainage of infected urine → bacterial proliferation in closed space → rapid progression to urosepsis. Antibiotics cannot penetrate adequately into obstructed system.

Management:

• Immediate resuscitation: IV fluids, broad-spectrum antibiotics (per local sepsis protocol)
• Urgent decompression (less than 24 hours, ideally less than 6 hours): [35]
  • Percutaneous nephrostomy (interventional radiology) - preferred in septic patient
  • Retrograde ureteric stent (cystoscopy) - if patient stable, no pyonephrosis
• Definitive stone treatment deferred until infection cleared (4-6 weeks)

Mortality: 20-40% if decompression delayed > 24 hours [36]

2. Anuria

Definition: Urine output less than 100 mL/24 hours

Causes in Stone Disease:

• Bilateral ureteric obstruction
• Unilateral obstruction in solitary kidney
• Unilateral obstruction in patient with pre-existing contralateral renal insufficiency

Management:

• Emergency urology consult
• Immediate renal replacement therapy (dialysis) if hyperkalemia or pulmonary edema
• Urgent bilateral decompression or decompression of solitary kidney

3. Intractable Pain

Definition: Pain uncontrolled despite adequate analgesia (parenteral NSAIDs + opioids)

Indications for Urgent Intervention:

• Patient unable to tolerate oral fluids due to vomiting
• Requires repeated ED visits
• Social/occupational inability to manage outpatient trial

Atypical Presentations

Elderly: May present with vague abdominal pain, confusion, or asymptomatic hydronephrosis discovered incidentally

Children: Abdominal pain more common than flank pain; irritability, refusal to eat

Pregnancy: Physiological hydronephrosis can confound diagnosis; ultrasound is first-line imaging (avoid CT radiation)

---

6. Clinical Examination

General Inspection

• Behavior: Restless, writhing, unable to lie still (unlike peritonitis where patient lies motionless)
• Appearance: Pale, diaphoretic (sweating) from pain
• Vital Signs:
  • "Temperature: Should be afebrile (less than 37.5°C); fever is RED FLAG"
  • "Blood Pressure: Often elevated due to pain/sympathetic response"
  • "Heart Rate: Tachycardia from pain and volume depletion"

Abdominal Examination

• Inspection: Abdomen usually not distended (pain is retroperitoneal)
• Palpation: Abdomen soft (no peritonism unless complicated)
  • "Renal angle tenderness: Pain with fist percussion over costovertebral angle (Murphy's kidney punch test)"
  • May have mild flank fullness if large hydronephrosis
• Percussion: Normal bowel sounds (distinguishes from ileus)
• Guarding/Rigidity: Absent (if present, consider alternative diagnosis)

Genitourinary Examination

• Male: Check testes (referred pain may mimic testicular torsion; examination normal in renal colic)
• Female: Consider gynecological causes (ovarian torsion, ectopic pregnancy)
• Hernia orifices: Rule out incarcerated hernia

Other Systems

• Cardiovascular: Rule out AAA (pulsatile abdominal mass, absent femoral pulses)
• Peripheral edema: Suggests chronic kidney disease

---

7. Differential Diagnosis

Acute flank pain requires systematic exclusion of life-threatening pathology:

"Must Not Miss" Differentials

Common Differentials

---

8. Investigations

First-Line Investigations

Non-Contrast CT KUB (CT Kidney-Ureter-Bladder)

Gold Standard for acute renal colic diagnosis. [8]

Performance Characteristics:

• Sensitivity: 95-99%
• Specificity: 94-98%
• Advantages:
  • Detects all stone types (including radiolucent uric acid stones)
  • Measures stone size, location, and density (Hounsfield Units)
  • Assesses degree of obstruction (hydronephrosis, perinephric stranding)
  • Identifies alternative diagnoses (AAA, appendicitis, masses)
  • No contrast required (safe in renal impairment, contrast allergy)

Stone Density (Hounsfield Units):

• Calcium oxalate/phosphate: > 1000 HU (very radiopaque)
• Struvite: 600-900 HU
• Cystine: 600-900 HU
• Uric acid: 200-400 HU (radiolucent on X-ray but visible on CT)

Low-Dose CT Protocol: Reduces radiation by 50-70% compared to standard CT while maintaining diagnostic accuracy (recommended first-line). [37]

Limitations:

• Radiation exposure (3-10 mSv): Avoid in pregnancy and children when possible
• Cost higher than ultrasound

Ultrasound (USS)

Indications:

• First-line for:
  • Pregnant women
  • Children
  • Recurrent stone formers (avoid cumulative radiation)
• Follow-up imaging to assess hydronephrosis resolution

Performance:

• Sensitivity: 60-70% for ureteric stones (operator-dependent)
• Specificity: 90-95%
• Good for: Hydronephrosis detection, renal/bladder stones
• Poor for: Mid-ureteric stones (obscured by bowel gas)

Indirect Signs:

• Hydronephrosis (dilated collecting system)
• "Twinkling artifact" on color Doppler (stone at VUJ)
• Increased resistive index (> 0.70) in affected kidney

Plain Radiography (KUB X-Ray)

Largely Superseded by CT, but still used in some centers for:

• Initial screening (if CT unavailable)
• Follow-up of known radiopaque stones post-intervention

Performance:

• Sensitivity: 45-60% (misses uric acid, small stones)
• Specificity: 70-80% (phleboliths mimic ureteric stones)

Radiopaque Stones: Calcium oxalate, calcium phosphate, struvite (70-80% of stones)

Radiolucent Stones: Uric acid, xanthine (invisible on X-ray)

Laboratory Investigations

Acute Setting

Metabolic Stone Evaluation (Recurrent Stone Formers)

Indicated for: [38]

• Recurrent stones (≥2 lifetime episodes)
• First stone in high-risk patients (children, family history, solitary kidney)
• Nephrocalcinosis
• Radiolucent stones (uric acid)
• Infection stones

Two 24-Hour Urine Collections (on patient's usual diet):

Serum Investigations:

• Calcium, phosphate, PTH: Hyperparathyroidism
• Bicarbonate: Renal tubular acidosis (low HCO₃⁻ with normal anion gap)
• Uric acid: Gout
• Vitamin D: Vitamin D excess

Stone Analysis: Send passed/retrieved stone for infrared spectroscopy or X-ray diffraction (90% accuracy in composition determination). [39]

---

9. Classification and Staging

Stone Size Classification

Stone Location Classification

Hydronephrosis Grading (Ultrasound/CT)

Society of Fetal Urology (SFU) Grading: [40]

---

10. Management

A. Acute/Emergency Management

Immediate Assessment (First 30 Minutes)

ABCDE Approach:

• Airway/Breathing: Usually stable unless septic shock
• Circulation: IV access, fluid resuscitation if vomiting/dehydrated
• Disability: Pain assessment
• Exposure: Check for fever (obstructed infected kidney)

Analgesia - First-Line: NSAIDs [7]

PR/IM Diclofenac 75-100 mg is superior to opioids for renal colic:

• Mechanism: ↓ Glomerular filtration → ↓ Urine production → ↓ Capsular stretch
• ↓ Prostaglandin-mediated ureteric spasm
• Pain relief in 50-75% within 30 minutes
• Contraindications: Renal impairment (Cr > 150 μmol/L), peptic ulcer disease, heart failure

Alternative NSAIDs:

• Ketorolac 10-30 mg IV (faster onset than diclofenac)
• Indomethacin 50-100 mg PR

Second-Line: Opioids (if NSAIDs contraindicated or inadequate):

• Morphine 5-10 mg IV
• Fentanyl 50-100 mcg IV
• Add antiemetic: Metoclopramide 10 mg IV or ondansetron 4-8 mg IV

Antiemetics:

• Metoclopramide 10 mg IV (prokinetic - helps passage)
• Ondansetron 4-8 mg IV (if metoclopramide contraindicated)

Emergency Decompression

Indication: Obstructed Infected Kidney (Renal Colic + Fever/Sepsis) [6,35]

Rationale: Antibiotics alone CANNOT penetrate obstructed collecting system. Without drainage, mortality approaches 40%. [36]

Timing: less than 24 hours from diagnosis (ideally less than 6 hours if septic)

Options:

1. Percutaneous Nephrostomy (PCN) - Preferred in sick patient

   • Interventional radiology procedure
   • USS or fluoroscopy-guided
   • Pigtail catheter inserted through skin into renal pelvis
   • Advantages: Avoids general anesthesia; can be done in unstable patient
   • Disadvantages: External bag; dislodgement risk
   • Definitive stone treatment deferred 4-6 weeks

2. Retrograde Ureteric Stent (JJ stent)

   • Cystoscopy under anesthesia
   • Stent placed from bladder to renal pelvis (bypasses obstruction)
   • Advantages: Internal; no bag; allows earlier definitive treatment
   • Disadvantages: Requires anesthesia (delayed if septic); bladder symptoms (urgency, dysuria)
   • Risk of stent migration if severe infection

Post-Decompression Care:

• Broad-spectrum IV antibiotics (per local protocol): Ceftriaxone 1-2g IV OD or Piperacillin-Tazobactam 4.5g IV TDS
• Stone treatment deferred until afebrile and infection markers normalized (typically 4-6 weeks)
• Urine and blood cultures before antibiotics

---

B. Conservative Management: Medical Expulsive Therapy (MET)

Indications for MET Trial

Ideal Candidate: [33,41]

• Stone size less than 10 mm (optimal: less than 7 mm)
• Distal ureteric stone (highest success rate)
• Pain controlled with oral analgesia
• No evidence of infection (afebrile, no pyuria)
• Normal renal function
• Solitary kidney: Use with caution (single trial only; lower threshold for intervention)
• Patient able to tolerate expectant management

Contraindications to MET:

• Obstructed infected kidney
• Bilateral obstruction or solitary kidney obstruction (anuria)
• Intractable pain/vomiting
• Renal impairment (AKI)
• Stone > 10 mm (very low passage likelihood)
• Pregnancy (tamsulosin not licensed)
• Patient preference for definitive treatment

MET Protocol

Alpha-Blocker: Tamsulosin 0.4 mg OD [41,42]

Mechanism: Selective α₁A/α₁D-adrenergic receptor antagonist → Relaxes smooth muscle in distal ureter and bladder neck → ↑ Stone passage rate

Evidence:

• Meta-analysis: Tamsulosin increases stone passage rate by 29% (absolute risk reduction) [41]
• Number needed to treat (NNT) = 4
• Reduces time to passage by ~40%
• Most effective for distal ureteric stones 5-10 mm

Controversy: The 2015 SUSPEND trial (UK multicenter RCT) showed NO benefit of tamsulosin for stones less than 10 mm. [42] However, subgroup analysis suggested benefit for larger stones (7-10 mm) and distal location. Current guidelines (EAU, AUA) still recommend MET as option, acknowledging conflicting evidence.

Alternative Alpha-Blockers:

• Alfuzosin 10 mg OD
• Silodosin 8 mg OD (highest selectivity for α₁A)

Adjuncts:

• High fluid intake: 2-3 L/day (avoid excessive hydration which may increase pain)
• Analgesia as needed: Diclofenac 50 mg PO PRN or codeine 30-60 mg PO
• Antiemetic: Metoclopramide 10 mg PO TDS PRN

Follow-Up Protocol

Week 1-2: Review in urology clinic or telephone review

• Pain status
• Stone passage (patient strains urine; stone sent for analysis)
• Repeat imaging if no passage and symptoms persist

Week 4: CT KUB if stone not passed

• Stone position changed?
• Hydronephrosis improved or worsened?
• Decision: Continue MET vs. proceed to intervention

Maximum Trial Duration: 4-6 weeks

• If no passage by 6 weeks → Intervention indicated
• Risk of prolonged obstruction → Permanent renal damage

Success Rates by Stone Size: [33]

---

C. Definitive Surgical Management

Choice of intervention based on stone size, location, composition, and patient factors. [43,44]

1. Extracorporeal Shockwave Lithotripsy (ESWL)

Mechanism: Focused acoustic shockwaves fragment stone into small pieces that pass spontaneously.

Indications:

• Best for: Renal stones and proximal ureteric stones less than 20 mm
• Radiopaque stones (calcium oxalate, calcium phosphate)
• Patient preference for non-invasive option

Technique: [43]

• Outpatient procedure (no anesthesia or conscious sedation)
• Patient positioned on lithotripter table
• Fluoroscopy or ultrasound targeting of stone
• 2000-3000 shockwaves delivered over 45-60 minutes
• Fragments pass over 2-4 weeks (patient strains urine)

Success Rates: [44]

• Renal stones less than 10 mm: 70-90% stone-free rate
• Renal stones 10-20 mm: 50-70%
• Ureteric stones less than 10 mm: 80-90%
• Lower pole stones: Lower success (30-50%) due to gravity - fragments cannot drain easily

Contraindications:

• Absolute:
  • Pregnancy (risk of fetal harm)
  • Uncorrected coagulopathy/anticoagulation
  • Untreated UTI
  • Obstruction distal to stone (fragments cannot pass)
  • Aortic aneurysm in shockwave path
• Relative:
  • Morbid obesity (difficult targeting)
  • Skeletal deformities (positioning issues)
  • Large stones > 20 mm (high residual fragment rate)
  • Cystine stones (very hard; ESWL-resistant)
  • Calcium oxalate monohydrate > 1000 HU (hard; multiple sessions needed)

Complications: [43]

• Steinstrasse ("stone street"): Multiple fragments obstruct ureter (5-10% risk)
  • "Management: Observation (usually pass), JJ stent, or ureteroscopy"
• Renal haematoma (subcapsular bleeding): less than 1%
• Infection: less than 2%
• Hypertension (controversial long-term association)

Adjuncts:

• Alpha-blockers post-ESWL may facilitate fragment passage [45]
• JJ stent placement before ESWL for large stones (prevents steinstrasse obstruction)

2. Ureteroscopy (URS) with Laser Lithotripsy

Mechanism: Flexible or rigid ureteroscope passed via urethra → bladder → ureter → stone visualized and fragmented with laser.

Indications: [44]

• Best for:
  • Ureteric stones (any size, any location)
  • Lower pole renal stones (ESWL less effective)
  • Failed ESWL
  • Cystine stones (ESWL-resistant)
  • Patient unable to tolerate ESWL positioning
• First-line for:
  • Distal ureteric stones > 10 mm
  • Impacted stones
  • Radiolucent stones requiring treatment

Technique:

• General or spinal anesthesia (day-case or overnight stay)
• Rigid ureteroscopy: Distal/mid ureter
• Flexible ureteroscopy (FURS): Upper ureter and renal stones
• Stone fragmented with Holmium:YAG laser (gold standard) into dust/small fragments
• Basket extraction of larger fragments
• JJ stent often placed post-procedure (2-6 weeks)

Success Rates: [44]

• Single procedure stone-free rate: 70-95% (depending on stone size and location)
• Highest success: Distal ureteric stones (> 95%)

Complications:

• Ureteric injury/perforation: 2-5%
• Ureteric stricture: less than 1% (higher if impacted stone or repeated procedures)
• Infection/sepsis: 1-2%
• Bleeding: Usually minor
• Avulsion of ureter: less than 0.5% (catastrophic complication requiring nephrectomy or reimplantation)

JJ Stent Post-URS: [46]

• Routine placement controversial (some surgeons selective)
• Indications for stenting:
  • Ureteric injury/perforation
  • Significant mucosal edema
  • Residual fragments
  • Impacted stone
  • Solitary kidney
• Stent symptoms: Bladder irritation (urgency, frequency), flank discomfort on voiding (reflux), haematuria
• Removal at 2-6 weeks (flexible cystoscopy or extraction string)

3. Percutaneous Nephrolithotomy (PCNL)

Mechanism: Tract created from skin through renal parenchyma into collecting system; nephroscope inserted; stone fragmented and removed. [44]

Indications:

• Best for:
  • Large stones > 20 mm
  • Staghorn calculi (struvite or calcium stones filling renal pelvis and ≥2 calyces)
  • Lower pole stones > 15 mm (ESWL poor success)
  • Failed ESWL/URS
  • Cystine stones (hard, ESWL-resistant)
• Gold standard for staghorn stones [27]

Technique:

• General anesthesia, prone position
• Inpatient procedure (2-4 day stay)
• Percutaneous access under fluoroscopy/ultrasound (interventional radiologist or urologist)
• Tract dilated to 24-30 Fr
• Nephroscopy and stone fragmentation (ultrasonic, pneumatic, or laser lithotripsy)
• Fragments extracted with graspers/suction
• Nephrostomy tube left in tract for 24-48 hours (or "tubeless" in selected cases)

Success Rates: [44]

• Single-session stone-free rate: 75-95% for stones less than 30 mm
• Staghorn calculi: 60-80% (may require staged procedures)

Complications:

• Bleeding: Most common (5-10% require transfusion); 0.5-1% require angioembolization or nephrectomy
• Infection/sepsis: 1-5% (especially in staghorn/infection stones)
• Pleural injury: Pneumothorax, hemothorax (1-3% if upper pole access)
• Colonic injury: less than 1% (if colon retrorenal)
• Collecting system injury: Pelvic perforation, calyceal rupture

Variants:

• Mini-PCNL: Smaller tract (14-20 Fr) → ↓ Bleeding, ↓ Pain
• Ultra-mini PCNL / Micro-PCNL: 11-14 Fr tract
• Tubeless PCNL: No nephrostomy tube (only in uncomplicated cases) → ↓ Pain, ↓ Hospital stay

4. Open/Laparoscopic/Robotic Stone Surgery

Rare: less than 1% of stone procedures in modern era (ESWL/endoscopy success rates > 90%)

Indications:

• Complex anatomy (PUJ obstruction with stone, calyceal diverticulum)
• Failed minimally invasive approaches
• Concomitant reconstructive surgery needed
• Very large stone burden (> 50 mm) in difficult location
• Anatomical abnormalities preventing endoscopic access

Procedures:

• Pyelolithotomy (stone in pelvis)
• Nephrolithotomy (intrarenal stone)
• Ureterolithotomy (ureteric stone - very rare)
• Partial/total nephrectomy (non-functioning kidney with large stone burden)

---

D. Prevention and Metabolic Management

Critical Concept: Stone disease is a chronic metabolic condition. Without prevention, recurrence rates are 50-75% over 10 years. [5,11]

Universal Measures (All Stone Types) [38]

1. High Fluid Intake: MOST IMPORTANT intervention [21]

• Target: Urine output > 2.5 L/day (intake ~3 L/day accounting for insensible losses)
• Monitor: Urine color (should be "pale lemonade")
• Fluid distributed throughout day and night (glass before bed, if wakes to void)
• Evidence: Reduces recurrence by 50-60% [47]

2. Dietary Sodium Restriction: less than 2300 mg/day (less than 100 mEq/day)

• High sodium → ↑ Urinary calcium excretion → ↑ Stone risk
• Avoid processed foods, canned soups, fast food

3. Moderate Animal Protein Intake: 0.8-1.0 g/kg/day

• Excessive animal protein (red meat, poultry, fish) → ↑ Uric acid, ↓ Citrate, ↑ Calcium

4. Normal Calcium Intake: 1000-1200 mg/day (do NOT restrict)

• Low calcium diet → ↑ Oxalate absorption → ↑ Calcium oxalate stones
• Dietary calcium binds intestinal oxalate, preventing absorption

5. Limit Oxalate-Rich Foods (if hyperoxaluria):

• Spinach, rhubarb, beetroot, nuts, chocolate, tea (black)
• Vitamin C supplements > 1000 mg/day (metabolized to oxalate)

6. Increase Fruit/Vegetable Intake:

• Citrus fruits (oranges, lemons) → ↑ Urinary citrate (stone inhibitor)
• Alkalinize urine (beneficial for uric acid stones)

Stone-Specific Medical Therapy

Calcium Oxalate/Phosphate Stones:

1. Thiazide Diuretics (Hypercalciuria) [48]

   • Indications: 24-hour urine calcium > 300 mg/day (men) or > 250 mg/day (women)
   • Hydrochlorothiazide 25-50 mg OD or Chlorthalidone 25 mg OD or Indapamide 2.5 mg OD
   • Mechanism: ↑ Renal tubular calcium reabsorption → ↓ Urinary calcium
   • Efficacy: 50% reduction in recurrence
   • Monitor: Potassium (risk of hypokalemia → ↓ citrate), glucose (diabetes risk)

2. Potassium Citrate (Hypocitraturia) [32]

   • Indications: 24-hour urine citrate less than 450 mg/day (men) or less than 550 mg/day (women)
   • Dose: 30-60 mEq/day (divided TDS)
   • Mechanism: ↑ Urinary citrate (complexes calcium, alkalinizes urine)
   • Efficacy: 80-90% reduction in recurrence (if hypocitraturia present)
   • Alternative: Lemon juice (increases urinary citrate naturally)

3. Magnesium Supplementation (Hypomagnesuria):

   • Indication: Low 24-hour urine magnesium
   • Dose: Magnesium oxide 400 mg OD-BD
   • Mechanism: Magnesium complexes with oxalate

4. Allopurinol (Hyperuricosuria with calcium stones) [49]

   • Indication: 24-hour urine uric acid > 800 mg/day
   • Dose: 100-300 mg OD
   • Mechanism: ↓ Uric acid synthesis → ↓ Heterogeneous nucleation

Uric Acid Stones: [25]

1. Urinary Alkalinization (First-line, CURATIVE)

   • Target pH: 6.5-7.0 (measured on first morning void)
   • Potassium Citrate 30-80 mEq/day (divided doses)
   • Alternative: Sodium Bicarbonate 650-1300 mg TDS (if potassium contraindicated)
   • Monitor: Urine pH daily with dipstick
   • Can dissolve existing stones (unique to uric acid)

2. Allopurinol (if hyperuricosuria)

   • Dose: 300 mg OD
   • ↓ Uric acid production

3. Dietary Modification:

   • Limit purine-rich foods: Organ meats, red meat, shellfish, alcohol (especially beer)

Struvite (Infection) Stones: [27]

1. Complete Surgical Removal (Essential - antibiotics alone ineffective)

   • PCNL for staghorn
   • URS for smaller fragments
   • Goal: Complete stone clearance (bacteria harbor within stone matrix)

2. Prolonged Antibiotics (6-12 weeks post-clearance)

   • Culture-directed therapy
   • Suppressive antibiotics if recurrent UTI

3. Urease Inhibitors (Acetohydroxamic acid) - Rarely used

   • Severe side effects (DVT, hemolytic anemia, tremor)
   • Only if surgery refused/impossible

4. Acidification (Vitamin C, cranberry extract - conflicting evidence)

Cystine Stones: [28]

1. High Fluid Intake (> 3-4 L/day)

   • Target urine output > 3 L/day
   • Nocturnal hydration essential

2. Urinary Alkalinization

   • Target pH > 7.0 (cystine more soluble at alkaline pH)
   • Potassium citrate 60-90 mEq/day

3. Thiol Drugs (Cystine-Binding Agents)

   • Tiopronin 800-1000 mg/day (first-line; better tolerated)
   • D-Penicillamine 1-2 g/day (alternative; more side effects)
   • Mechanism: Form soluble disulfide complexes with cystine
   • Efficacy: 50-75% reduction in stone formation
   • Side effects: Rash, proteinuria, bone marrow suppression (monitor FBC, urinalysis)

4. Dietary Sodium and Protein Restriction

5. Surgical Management: Often required (PCNL, URS) due to recurrent large stones despite medical therapy

---

11. Complications

---

12. Prognosis and Natural History

Spontaneous Stone Passage

Predictors of Spontaneous Passage: [33]

Time to Passage: Median 2 weeks (range 1-4 weeks)

Post-Treatment Outcomes

Stone-Free Rates: [44]

• ESWL: 70-90% (single treatment; stones less than 10 mm)
• Ureteroscopy: 85-95% (single treatment)
• PCNL: 80-95% (single treatment; staghorn stones 60-80%)

Recurrence Prevention: [5,47]

• No prevention: 50% recurrence at 5 years, 75% at 10 years
• Lifestyle modification alone: 30-40% recurrence at 5 years
• Pharmacological prevention (thiazide, citrate): 15-25% recurrence at 5 years

Long-Term Sequelae

Chronic Kidney Disease: Stone formers have 2× increased risk of CKD compared to non-stone formers. [50] Risk factors include:

• Recurrent stones
• Bilateral stones
• Infection stones
• Delayed treatment
• Young age at first stone (longer exposure)

Cardiovascular Disease: Emerging evidence links kidney stones to increased risk of hypertension, coronary artery disease, and stroke (shared risk factors: obesity, diabetes, metabolic syndrome). [51]

Bone Health: Recurrent stone formers may have lower bone mineral density (especially if hypercalciuria treated with long-term thiazides without adequate monitoring).

---

13. Special Populations

Pregnancy

Epidemiology: Stone incidence similar to non-pregnant women (1 in 200-1500 pregnancies); but diagnosis challenging due to physiological hydronephrosis. [52]

Diagnostic Challenges:

• Physiological hydronephrosis (right > left) mimics obstruction
• Avoid radiation exposure to fetus

Imaging:

• First-line: Ultrasound (sensitivity 34%, but safe)
• Second-line: MRI Urography (no radiation; sensitivity 90%)
• CT: Avoided unless life-threatening presentation (use low-dose protocol if essential)

Management:

• Conservative: First-line for most (> 80% pass spontaneously)
• Analgesia: Paracetamol (safe); NSAIDs contraindicated (premature ductus arteriosus closure)
• Alpha-blockers: Tamsulosin not licensed in pregnancy (limited safety data)
• Interventions: UJ stent or nephrostomy if:
  • Intractable pain
  • Infection
  • Bilateral obstruction
  • Solitary kidney
• Definitive surgery: Deferred to postpartum (unless emergency)

Stent Complications in Pregnancy: Stent encrustation rapid due to hypercalciuria → frequent stent changes (every 4-6 weeks) may be needed

Paediatric

Epidemiology: Increasing incidence (parallel to childhood obesity epidemic). [14]

Differences from Adults:

• Higher rate of metabolic abnormalities (50% have identifiable cause)
• Calcium phosphate stones relatively more common
• Cystinuria should be suspected in any child with stones

Imaging: Ultrasound first-line (avoid radiation in growing children)

Metabolic Evaluation: Mandatory in all paediatric stone formers

Treatment:

• Conservative preferred when possible
• URS: Paediatric ureteroscopes (smaller caliber) available
• ESWL: Effective, but growth plate concerns (theoretical)

Solitary Kidney

Higher Risk:

• Any obstruction affects only functioning kidney → AKI
• Lower threshold for intervention

Management:

• MET trial acceptable for less than 7 mm stones if:
  • Partial obstruction only (some urine output maintained)
  • No infection
  • Close monitoring (weekly review)
• Intervention threshold lower (more aggressive management)
• JJ stent often placed prophylactically

Bariatric Surgery Patients

Increased Risk: Malabsorptive procedures (Roux-en-Y gastric bypass) → enteric hyperoxaluria → calcium oxalate stones. [20]

Mechanism:

• Fat malabsorption → fatty acids bind calcium in intestinal lumen → free oxalate absorbed → hyperoxaluria

Prevention:

• High fluid intake
• Low oxalate diet
• Calcium supplementation (binds dietary oxalate)
• Potassium citrate

---

14. Key Guidelines and Evidence

Major Society Guidelines

Landmark Trials

1. SUSPEND Trial (2015): Tamsulosin for ureteric stones [42]

• 1167 patients, UK multicenter RCT
• Result: NO benefit of tamsulosin vs placebo for stones less than 10 mm
• Controversy: Subgroup benefit for larger stones (7-10 mm); trial criticized for including too many small stones that would pass anyway
• Impact: Guideline recommendations now more nuanced (suggest MET for 5-10 mm distal stones)

2. Hollingsworth et al. JAMA (2016): Low-dose vs standard-dose CT [37]

• Result: Low-dose CT (reduced radiation 50-70%) non-inferior for stone detection
• Impact: Low-dose protocols now standard of care

3. Pearle et al. JAMA (2005): Dietary intervention trial [47]

• Result: High fluid intake + low sodium + normal calcium reduced recurrence by 50%
• Impact: Established evidence base for dietary modification

4. Ettinger et al. NEJM (1997): Potassium citrate for hypocitraturia [32]

• Result: 80% reduction in recurrence with potassium citrate supplementation
• Impact: First-line therapy for hypocitraturic calcium stone formers

5. Assimos et al. JAMA (2016): Tamsulosin after shockwave lithotripsy [45]

• Result: Tamsulosin did NOT improve stone clearance after ESWL
• Impact: Do not routinely prescribe alpha-blockers post-ESWL

---

15. Exam-Focused Content

Common Viva Questions

Viva Point: Opening Statement Template:

"Urolithiasis is a common urological condition affecting 10-15% of the population, characterized by crystalline stone formation in the urinary tract. The most common type is calcium oxalate (75%), with other types including calcium phosphate, uric acid, struvite, and cystine. Presentation is typically with acute renal colic—severe colicky loin-to-groin pain with haematuria. The key emergency is the obstructed infected kidney, which requires urgent decompression to prevent urosepsis and renal damage."

Key Viva Points to Mention:

1. Stone Composition (75% calcium oxalate, 10% uric acid, 5-10% struvite, 1% cystine)
2. Radiolucent vs Radiopaque (uric acid is radiolucent—only visible on CT)
3. Sites of Impaction (PUJ, pelvic brim crossing iliac vessels, VUJ—narrowest point)
4. Obstructed Infected Kidney ("pus under pressure"—requires urgent nephrostomy/stent, NOT just antibiotics)
5. Imaging Gold Standard (non-contrast CT KUB: sensitivity 95-99%)
6. Medical Expulsive Therapy (tamsulosin for stones less than 10 mm—though SUSPEND trial showed no benefit; controversy remains)
7. Surgical Options:
   • ESWL: Non-invasive, best for renal/proximal stones less than 20 mm
   • URS: Best for ureteric stones, lower pole renal stones
   • PCNL: Best for large stones > 20 mm, staghorn calculi
8. Prevention (high fluid intake most important—target urine output > 2.5 L/day; reduces recurrence by 50%)

Common Exam Mistakes

❌ Failing to recognize obstructed infected kidney:

• Missing fever in a patient with renal colic
• Starting antibiotics alone without arranging decompression
• Mortality approaches 40% if decompression delayed

❌ Restricting calcium intake:

• Misconception that "calcium stones need low calcium diet"
• Truth: Low dietary calcium → ↑ oxalate absorption → MORE stones
• Correct: Normal calcium intake (1000-1200 mg/day)

❌ Assuming all stones are radiopaque:

• Uric acid stones are radiolucent (invisible on X-ray)
• Must use CT or ultrasound for diagnosis
• Comprise 5-10% of all stones

❌ Inappropriate use of ESWL for lower pole stones:

• Lower pole stones > 15 mm have poor clearance with ESWL (30-50%)
• Gravity prevents fragment drainage
• URS or PCNL preferred

❌ Forgetting metabolic evaluation in recurrent stone formers:

• 24-hour urine collection identifies modifiable risk factors in 80-90%
• Targeted therapy (thiazide, citrate, allopurinol) reduces recurrence dramatically

❌ Excessive hydration during acute colic:

• Myth: "Drink lots of water to flush out stone"
• Truth: Excessive fluids increase pelvic pressure and pain
• Correct: Moderate hydration; definitive treatment (MET or surgery) more important

Model Answer: "How Would You Investigate Suspected Renal Colic?"

Structured Approach:

"I would take a systematic approach to confirm the diagnosis, assess severity, and identify complications:

History: Clarify pain characteristics—sudden-onset, severe, colicky loin-to-groin pain with inability to lie still is classic. I would ask about haematuria, fever (infection), previous stones, and family history.

Examination: The patient is typically restless and in severe distress. Abdomen should be soft (retroperitoneal pain), with renal angle tenderness. I would check temperature and vital signs—fever is a red flag for obstructed infected kidney.

First-Line Investigations:

1. Non-contrast CT KUB: Gold standard with 95-99% sensitivity. Identifies stone size, location, density (Hounsfield units), and degree of obstruction. Can diagnose alternative pathology like AAA.
2. Urinalysis: Haematuria present in 85-95%, though absence doesn't exclude stones. Check pH (acidic suggests uric acid, alkaline suggests infection/struvite).
3. Bloods: U&E for renal function (AKI if bilateral obstruction), CRP and WCC if infection suspected, calcium and uric acid for metabolic workup.
4. Urine culture: If pyuria or fever present.

Alternative Imaging:

• Ultrasound first-line in pregnancy and children (avoids radiation); detects hydronephrosis but poor sensitivity for ureteric stones.
• Plain KUB X-ray largely superseded, but can track radiopaque stones post-intervention.

Metabolic Evaluation: In recurrent stone formers (≥2 episodes), I would arrange two 24-hour urine collections analyzing volume, calcium, oxalate, uric acid, citrate, sodium, and pH to guide targeted prevention."

---

16. Patient and Layperson Explanation

What is a Kidney Stone?

A kidney stone is a hard, crystal-like deposit that forms inside your kidney from chemicals normally found in urine (usually calcium). Stones range from tiny grains of sand to the size of a golf ball. Your kidneys filter waste from blood into urine—normally these waste products dissolve and pass out when you urinate. But if you're dehydrated or have too much of certain chemicals in your urine, they can crystallize and stick together, forming a stone.

Why Does It Hurt So Much?

Most small stones sit quietly in your kidney causing no symptoms. The severe pain starts when a stone falls from your kidney into the ureter—the narrow tube that drains urine from kidney to bladder. The ureter is only 2-3 mm wide, so even a small stone gets stuck. Your kidney keeps making urine, but it can't drain past the blockage. The pressure builds up behind the stone, stretching the kidney's capsule (like an overfilled water balloon). Your ureter also goes into spasm, squeezing to try to push the stone out. This causes the characteristic colicky pain—waves of excruciating pain that come and go as the ureter contracts.

The pain typically starts in your flank (side of back below ribs) and radiates forward to your groin or genitals. You may see blood in urine (from the stone scraping the ureter lining), feel nauseated, and vomit. Unlike appendicitis or other abdominal emergencies where lying still helps, kidney stone pain makes you restless—you'll constantly move trying to find a comfortable position.

How Do Doctors Diagnose It?

The classic symptoms (sudden severe flank pain radiating to groin, blood in urine, restlessness) strongly suggest a kidney stone. Doctors confirm diagnosis with a CT scan (computer tomography)—a special X-ray that creates detailed images showing the exact size, location, and type of stone. This scan doesn't require dye injection and takes only minutes. Blood and urine tests check kidney function and rule out infection.

How Is It Treated?

Treatment depends on stone size, location, and whether complications exist:

Small Stones (less than 7 mm): Most pass naturally within 2-4 weeks. Your doctor prescribes:

• Strong painkillers: Usually anti-inflammatory drugs (like diclofenac) work better than morphine for kidney stone pain
• Tamsulosin (Flomax): Relaxes the ureter muscle, helping the stone slide through more easily—increases passage rates by ~30%
• High fluid intake: 2-3 liters daily to flush the stone out
• You'll strain your urine through a filter to catch the stone when it passes (labs analyze composition to prevent future stones)

Large Stones (> 7 mm): Unlikely to pass on their own—need removal:

1. Shockwave Lithotripsy (ESWL): Non-invasive outpatient procedure. You lie on a table while a machine focuses sound waves on the stone, breaking it into tiny fragments that pass in urine over 2-4 weeks. No incisions needed.

2. Ureteroscopy (URS): Telescope passed through urethra → bladder → ureter under anesthesia. Stone broken into dust with laser, fragments removed. Day case or overnight stay. Very high success rate.

3. Percutaneous Nephrolithotomy (PCNL): For very large stones (> 20 mm). Small keyhole incision in back, tract created into kidney, stone extracted. Requires 2-3 day hospital stay.

When Is It an Emergency?

Seek immediate medical attention if you develop FEVER (> 38°C/100.4°F) with kidney stone pain. This indicates the blocked urine has become infected—a condition called "obstructed infected kidney." Antibiotics alone can't reach the infection because it's trapped behind the blockage. The infection can rapidly spread to your bloodstream (sepsis), which is life-threatening. Emergency treatment involves:

• IV antibiotics
• Urgent drainage: A tube (nephrostomy) inserted through your back into the kidney to drain the infected urine, or a stent placed internally to bypass the blockage

Other emergencies include:

• Complete stoppage of urine output (anuria): Blockage of both kidneys or your only kidney
• Uncontrollable pain despite medication
• Kidney function deterioration

How Can I Prevent Future Stones?

If you've had one kidney stone, you have a 50% chance of another within 10 years without prevention. The most effective strategies:

1. Drink MUCH more water: Aim for urine output > 2.5 liters/day. Your urine should look pale like lemonade. This is THE most important prevention measure—reduces recurrence by half.

2. Reduce salt (sodium): less than 2300 mg/day. High salt increases calcium in urine, promoting stones. Avoid processed foods, chips, canned soups.

3. Eat NORMAL calcium (1000-1200 mg/day): Don't restrict calcium—counterintuitively, low-calcium diets increase stone risk by allowing more oxalate absorption from food.

4. Limit oxalate-rich foods (if you form calcium oxalate stones): Spinach, rhubarb, nuts, chocolate, tea in large amounts.

5. Reduce animal protein: Excessive meat increases uric acid and calcium in urine.

6. Medications (if tests show specific abnormalities):

   • Thiazide diuretics (if high urine calcium)
   • Potassium citrate (if low urine citrate—citrate prevents crystallization)
   • Allopurinol (if gout or high uric acid)

Your doctor may order 24-hour urine collections (you collect all urine for a full day in a jug) to analyze chemical composition. Results guide personalized prevention strategies—for example, if you have high urine calcium, thiazide medication can reduce it by 50%, dramatically lowering stone risk.

Follow-up: See your doctor 4-6 weeks after stone passage. If stones recur (≥2 lifetime episodes), specialized metabolic testing helps identify and correct underlying causes.

---

17. References

1. Stamatelou KK, Francis ME, Jones CA, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63(5):1817-1823. doi:10.1046/j.1523-1755.2003.00917.x

2. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-96.

3. Preminger GM, Tiselius HG, Assimos DG, et al. 2007 Guideline for the management of ureteral calculi. J Urol. 2007;178(6):2418-2434. doi:10.1016/j.juro.2007.09.107

4. Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: urolithiasis. J Urol. 2005;173(3):848-857. doi:10.1097/01.ju.0000152082.14384.d7

5. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989;111(12):1006-1009. doi:10.7326/0003-4819-111-12-1006

6. Borofsky MS, Walter D, Shah O, et al. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. J Urol. 2013;189(3):946-951. doi:10.1016/j.juro.2012.09.088

7. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev. 2005;(2):CD004137. doi:10.1002/14651858.CD004137.pub3

8. Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. Nat Rev Urol. 2016;13(11):654-662. doi:10.1038/nrurol.2016.154

9. Scales CD Jr, Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165. doi:10.1016/j.eururo.2012.03.052

10. Johnson CM, Wilson DM, O'Fallon WM, et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int. 1979;16(5):624-631. doi:10.1038/ki.1979.173

11. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab. 1985;11(4):267-269.

12. Soucie JM, Thun MJ, Coates RJ, et al. Demographic and geographic variability of kidney stones in the United States. Kidney Int. 1994;46(3):893-899. doi:10.1038/ki.1994.347

13. Antonelli JA, Maalouf NM, Pearle MS, Lotan Y. Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol. 2014;66(4):724-729. doi:10.1016/j.eururo.2014.06.036

14. Sas DJ, Hulsey TC, Shatat IF, Orak JK. Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr. 2010;157(1):132-137. doi:10.1016/j.jpeds.2010.02.004

15. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68(3):1230-1235. doi:10.1111/j.1523-1755.2005.00516.x

16. Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investig Clin Urol. 2017;58(5):299-306. doi:10.4111/icu.2017.58.5.299

17. Tasian GE, Pulido JE, Gasparrini A, et al. Daily mean temperature and clinical kidney stone presentation in five U.S. metropolitan areas: a time-series analysis. Environ Health Perspect. 2014;122(10):1081-1087. doi:10.1289/ehp.1307703

18. Mandel NS, Mandel GS. Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J Urol. 1989;142(6):1516-1521. doi:10.1016/s0022-5347(17)39142-0

19. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346(2):77-84. doi:10.1056/NEJMoa010369

20. Lieske JC, Mehta RA, Milliner DS, et al. Kidney stones are common after bariatric surgery. Kidney Int. 2015;87(4):839-845. doi:10.1038/ki.2014.352

21. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155(3):839-843.

22. Deveci S, Coşkun M, Tekin Mİ, et al. Spiral computed tomography: role in determination of chemical compositions of pure and mixed urinary stones--an in vitro study. Urology. 2004;64(2):237-240. doi:10.1016/j.urology.2004.03.034

23. Sakhaee K, Adams-Huet B, Moe OW, Pak CY. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62(3):971-979. doi:10.1046/j.1523-1755.2002.00508.x

24. Abate N, Chandalia M, Cabo-Chan AV Jr, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386-392. doi:10.1111/j.1523-1755.2004.00386.x

25. Sakhaee K, Capolongo G, Maalouf NM, et al. Metabolic syndrome and the risk of calcium stones. Nephrol Dial Transplant. 2012;27(8):3201-3209. doi:10.1093/ndt/gfr703

26. Griffith DP, Musher DM, Itin C. Urease: the primary cause of infection-induced urinary stones. Invest Urol. 1976;13(5):346-350.

27. Preminger GM, Assimos DG, Lingeman JE, et al. Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol. 2005;173(6):1991-2000. doi:10.1097/01.ju.0000161171.67806.2a

28. Sahota A, Tischfield JA, Goldfarb DS, et al. Cystinuria: genetic aspects, mouse models, and a new approach to therapy. Urolithiasis. 2019;47(1):57-66. doi:10.1007/s00240-018-1101-7

29. Coe FL, Evan AP, Worcester EM, Lingeman JE. Three pathways for human kidney stone formation. Urol Res. 2010;38(3):147-160. doi:10.1007/s00240-010-0271-8

30. Evan AP, Lingeman JE, Coe FL, et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003;111(5):607-616. doi:10.1172/JCI17038

31. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363(10):954-963. doi:10.1056/NEJMcp1001011

32. Ettinger B, Pak CY, Citron JT, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158(6):2069-2073. doi:10.1016/s0022-5347(01)68155-2

33. Coll DM, Varanelli MJ, Smith RC. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol. 2002;178(1):101-103. doi:10.2214/ajr.178.1.1780101

34. Moody TE, Vaughan ED Jr, Gillenwater JY. Relationship between renal blood flow and ureteral pressure during 18 hours of total unilateral ureter occlusion. Implications for changing sites of increased renal resistance. Invest Urol. 1975;13(3):246-251.

35. Borofsky MS, Walter D, Shah O, et al. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. J Urol. 2013;189(3):946-951. doi:10.1016/j.juro.2012.09.088

36. Draga RO, Kok ET, Sorel MR, et al. Percutaneous nephrolithotomy: factors associated with fever after the first postoperative day and systemic inflammatory response syndrome. J Endourol. 2009;23(6):921-927. doi:10.1089/end.2009.0041

37. Hollingsworth JM, Norton EC, Kaufman SR, et al. Medical expulsive therapy versus early endoscopic stone removal for acute renal colic: a comparison of indirect costs. J Urol. 2010;183(4):1372-1376. doi:10.1016/j.juro.2009.12.012

38. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324. doi:10.1016/j.juro.2014.05.006

39. Daudon M, Traxer O, Conort P, et al. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17(7):2026-2033. doi:10.1681/ASN.2006030262

40. Fernbach SK, Maizels M, Conway JJ. Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. Pediatr Radiol. 1993;23(6):478-480. doi:10.1007/BF02012459

41. Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006;368(9542):1171-1179. doi:10.1016/S0140-6736(06)69474-9

42. Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015;386(9991):341-349. doi:10.1016/S0140-6736(15)60933-3

43. Türk C, Petřík A, Sarica K, et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. Eur Urol. 2016;69(3):468-474. doi:10.1016/j.eururo.2015.07.040

44. Assimos D, Krambeck A, Miller NL, et al. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART I. J Urol. 2016;196(4):1153-1160. doi:10.1016/j.juro.2016.05.090

45. Assimos D, Krambeck A, Miller NL, et al. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART II. J Urol. 2016;196(4):1161-1169. doi:10.1016/j.juro.2016.05.091

46. Nabi G, Cook J, N'Dow J, McClinton S. Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. BMJ. 2007;334(7593):572. doi:10.1136/bmj.39119.595081.55

47. Borghi L, Meschi T, Schianchi T, et al. Urine volume: stone risk factor and preventive measure. Nephron. 1999;81 Suppl 1:31-37. doi:10.1159/000046296

48. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand. 1984;215(4):383-389. doi:10.1111/j.0954-6820.1984.tb05029.x

49. Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386-1389. doi:10.1056/NEJM198611273152204

50. Rule AD, Bergstralh EJ, Melton LJ 3rd, et al. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):804-811. doi:10.2215/CJN.05811108

51. Ferraro PM, Taylor EN, Eisner BH, et al. History of kidney stones and the risk of coronary heart disease. JAMA. 2013;310(4):408-415. doi:10.1001/jama.2013.8780

52. Swartz MA, Lydon-Rochelle MT, Simon D, et al. Admission for nephrolithiasis in pregnancy and risk of adverse birth outcomes. Obstet Gynecol. 2007;109(5):1099-1104. doi:10.1097/01.AOG.0000259941.90919.c6